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Abstract
We examined the effect of fluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, on the
production of hydroxyl radical (cOH) generation via nitric oxide synthase (NOS) activation by an in vivo microdialysis
technique. The microdialysis probe was implanted in the left ventricular myocardium of anesthetized rats and tissue was
perfused with Ringer’s solution through the microdialysis probe at a rate of 1 Wl/min. Sodium salicylate in Ringer’s solution
(0.5 nmol/Wl/min) was infused directly through a microdialysis probe to detect the generation of cOH. Induction of [K]o
(70 mM) or tyramine (1 mM), significantly increased the formation of cOH trapped as 2,3-dihydroxybenzoic acid (DHBA).
The application of NG-nitro-L-arginine methyl ester (L-NAME), a NOS inhibitor, significantly decreased the K
depolarization-induced cOH formation, but the effect of tyramine significantly increased the level of 2,3-DHBA. When
fluvastatin (100 WM), an inhibitor of low-density lipoprotein (LDL) oxidation, was administered to L-NAME-pretreated
animals, both KCl and tyramine failed to increase the level of 2,3-DHBA formation. The effect of fluvastatin may be
unrelated to K depolarization-induced cOH generation. To examine the effect of fluvastatin on ischemic/reperfused rat
myocardium, the heart was subjected to myocardial ischemia for 15 min by occlusion of the left anterior descending coronary
artery (LAD). When the heart was reperfused, a marked elevation of the level of 2,3-DHBA was observed. However, in the
presence of fluvastatin (100 WM), the elevation of 2,3-DHBA was not observed in ischemia/reperfused rat heart. Fluvastatin,
orally at a dose of 3 mg/kg/day for 4 weeks, significantly blunted the rise of serum creatine phosphokinase and improved the
electrocardiogram 2 h after coronary occlusion. These results suggest that fluvastatin is associated with a cardioprotective
effect due to the suppression of noradrenaline-induced cOH generation by inhibiting LDL oxidation in the heart. ß 2001
Elsevier Science B.V. All rights reserved.
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1. Introduction
Oxidative modi¢cation of low-density lipoprotein
(LDL) is a key event in early atherogenesis, which
contributes to cholesterol accumulation in the arteri-
al wall and the development of the atherosclerotic
lesion [1,2]. Fluvastatin, a 3-hydroxy-3-methylglutar-
yl coenzyme A (HMG-CoA) reductase inhibitor
[3,4], protects against the progression of atheroscle-
rosis and it is known to be a potent inhibitor of LDL
oxidation [5,6]. LDL is oxidized by transition metal
ions, such as copper and iron [5,7]. Although free
radical reactions are a part of normal metabolism,
the overproduction of reactive oxygen species such as
superoxide anion (O32 ), hydrogen peroxide (H2O2)
and hydroxyl radical (cOH) may contribute to cellu-
lar injury [8]. Oxygen-derived free radicals have been
implicated in the mediation of myocardial ischemia/
reperfusion injury [9]. Although £uvastatin has been
shown to have antioxidative properties [10^13], the
e¡ect of £uvastatin on nitric oxide (NO) is not well
known. NO is a free radical that regulates a variety
of biological functions and also has a role of in the
pathogenesis of cellular injury [14^16]. Cytotoxic free
radicals such as peroxinitrite (ONOO3) and cOH
may also be implicated in NO-mediated cell injury
[17]. NO is synthesized from L-arginine by NO syn-
thase (NOS) [18]. To con¢rm the cardioprotective
e¡ect of £uvastatin, we investigated the e¡ect of
NG-nitro-L-arginine methyl ester (L-NAME), a NOS
inhibitor, on cOH generation by an in vivo micro-
dialysis technique [19,20]. To achieve this goal, we
measured cOH formation in in vivo hearts, with the
use of a £exibly mounted microdialysis technique
that we developed [19].
2. Materials and methods
2.1. Animal preparation
Adult male Wistar rats weighing 300^400 g were
kept in an environmentally controlled room (20^
23‡C, 50^60% humidity, illuminated from 7.00 to
19.00 h) and fed with food and water ad libitum.
The rats were anesthetized with chloral hydrate
(400 mg/kg, i.p. ; Sigma, St. Louis, MO, USA) and
the level of anesthesia was maintained by intraperi-
toneal injection of chloral hydrate (20 mg/kg). After
intubation, the rat was mechanically ventilated with
room air supplemented with oxygen. The chest was
opened at the left ¢fth intercostal space, and the
pericardium was removed to expose the left ventricle.
The heart rate, arterial blood pressure, and electro-
cardiogram (ECG) were monitored and recorded
continuously. At the end of the experiments the
rats were killed by an overdose of anesthetic. All
procedures in dealing with the experimental animals
met the guideline principles stipulated by the Physio-
logical Society of Japan and the Animal Ethics Com-
mittee of the Oita Medical University.
2.2. Microdialysis technique
Details of the £exibly mounted microdialysis
technique and its application to measure biological
substances in the interstitial space have been de-
scribed previously [19]. We created a suitable micro-
dialysis probe. The tubes of the dialysis probe (ap-
prox. 15 cm long) were supported loosely at the
midpoint on a rotatable stainless steel wire, so that
their movement was totally synchronized with a
rapid up-and-down movement of the tip caused by
the heart beats. The probe was implanted from
the epicardial surface into the left ventricular myo-
cardium to a depth of 3 mm and perfused through
an inlet tube. The synchronized movement of the
tip of the microdialysis probe with the beating ven-
tricle minimized the tissue injury that would other-
wise be caused by friction between the probe and
the muscle tissue. The tip of a microdialysis probe
(3 mm length and 220 Wm o.d. with the distal end
closed) was made of dialysis membrane (cellulose
hollow ¢ber of 10 Wm thick with 50 000 molecular
weight cuto¡). Two ¢ne silica tubes (150 Wm o.d.)
were inserted from the open end into the tip of the
microdialysis tube consisting of a cylinder-shaped di-
alysis membrane which served as the inlet for the
perfusate and the outlet for the dialysate, respec-
tively. The inlet tube was connected to a microinjec-
tion pump (Carnegie Medicine, CMA/100 Stock-
holm, Sweden), and the outlet tube was led to a
high performance liquid chromatography (HPLC)
pump.
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2.3. Experimental protocol
To ¢nd out the most appropriate perfusion rate,
we bathed the microdialysis probe in vitro in a 37‡C
Ringer’s solution that contained 1.0 WM noradrena-
line and the samples were collected at di¡erent per-
fusion speeds (0.5^5 Wl/min). Based on the data col-
lected from such experiments, we chose the most
pertinent perfusion rate of 1.0 Wl/min in the present
measurements of noradrenaline and the relative re-
covery of noradrenaline under this perfusion rate
was estimated to be 17.0 þ 0.7%. Oxygen free radicals
are very reactive, and the non-enzymatic cOH adduct
of salicylate, 2,3-dihydroxybenzoic acid (DHBA),
provides an assay of cOH formation [20,21]. The
cOH captured as the hydroxylated derivative of sali-
cylic acid was measured by HPLC with an electro-
chemical (EC) procedure. For trapping cOH radicals
[20,21] in the myocardium, sodium salicylate in Ring-
er’s solution (0.5 nmol/Wl/min) was perfused by a
microinjection pump and the basal level of 2,3-
DHBA during a de¢nite period of time was deter-
mined. Fluvastatin, KCl or tyramine was dissolved in
Ringer’s solution for perfusion through a microdial-
ysis probe into the myocardium. After a 30 min
washout with Ringer’s solution, £uvastatin was in-
troduced through the probe. Under a constant sup-
ply of £uvastatin, KCl or tyramine was perfused.
Samples (1.0 Wl/min) were collected into small col-
lecting tubes containing 0.1 N HClO4 and assayed
immediately for 2,3-DHBA by HPLC-EC. In the
case of the L-NAME-treated rats, L-NAME (5
mg/kg) was injected intravenously into the rats before
the experiments. In order to ascertain the protective
e¡ect of £uvastatin on myocardial infarction and re-
perfusion damage, the serum creatine phosphokinase
(CPK) assay was measured. We divided the animals
into two groups of ¢ve rats each: a non-treatment
group (control group) and a £uvastatin-pretreated
group. In the £uvastatin-pretreated group, £uvastatin
was orally administered once a day in a dose of
3 mg/kg for 4 weeks. Blood was collected from cath-
eterization of the carotid artery analyzed for CPK
using Iatrontec CK rate (A) (Iatron Laboratories).
2.4. Preparation of ischemic rats
After microdialysis probe implantation in the is-
chemic zone, the left anterior descending coronary
artery branch (LAD) was clamped by a thread
through a tube surrounding the coronary artery.
The heart was subjected to regional ischemia for
15 min by the occlusion of LAD followed by reper-
fusion for 60 min.
2.5. Analytical procedures
The dialysate samples were immediately injected
for analysis into an HPLC-EC system equipped
with a glassy carbon working electrode (Eicom, Kyo-
to, Japan) and an analytic reverse-phase column on
an Eicompak MA-5ODS column (5 Wm 4.6U150
mm; Eicom). The working electrode was set at a
detector potential of 0.75 V. Each liter of mobile
phase contained 1.5 g 1-heptanesulfonic acid sodium
salt (Sigma), 0.1 g Na2EDTA, 3 ml triethylamine
(Wako Pure Chemical Industries, Japan) and 125
ml acetonitrile (Wako) dissolved in H2O. The pH
of the solution was adjusted to 2.8 with 3 ml phos-
phoric acid (Wako).
Fig. 1. E¡ect of £uvastatin on KCl-induced cOH formation after
treatment with L-NAME. Animals treated with KCl (hatched
bar; 70 mM) after the application of L-NAME (50 mg/kg i.v.)
plus £uvastatin (solid bar; 100 WM) (closed circles) were com-
pared with animals treated with KCl only (open circles). Di¡er-
ences between the time courses of 2,3-DHBA were studied with
the Mann-Whitney U-test. Values are means þ S.E.M. for six
animals; *P6 0.05 versus pre-KCl value.
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2.6. Materials
Fluvastatin sodium (XU-62-320) was donated by
the Discovery Research Laboratory, Tanabe Seiyaku
(Saitama, Japan). Tyramine-HCl and sodium salicy-
late and its metabolites were purchased from Sigma.
These drugs were dissolved in Ringer’s solution con-
taining 147 mM NaCl, 2.3 mM CaCl2 and 4 mM
KCl, pH 7.4. L-NAME was purchased from Dojindo
Laboratories (Kumamoto, Japan).
2.7. Statistical analysis
All values are presented as means þ S.E.M. Di¡er-
ences between the time courses of the levels of 2,3-
DHBA were studied by means of the Mann-Whitney
U-test. The signi¢cance of di¡erence was determined
using ANOVA with Fisher’s post hoc test. A P value
of less than 0.05 was regarded as statistically signi¢-
cant.
3. Results
3.1. E¡ect of £uvastatin on high KCl-induced cOH
formation after L-NAME treatment
The cOH captured as the hydroxylated derivative
of salicylic acid was measured by the HPLC-EC pro-
cedure. The basal level of 2,3-DHBA in the heart
dialysate from control animals following infusion of
sodium salicylate (0.5 nmol/Wl/min) was 0.033 þ 0.007
WM. Time-dependent changes in the formation of
2,3-DHBA were monitored in the dialysate from
rat heart. Fluvastatin alone did not a¡ect the level
of 2,3-DHBA in the absence of sodium salicylate
(data not shown). The e¡ects of £uvastatin, an in-
hibitor of LDL oxidation, on extracellular potassium
ion concentration, [K]o (70 mM)-induced cOH for-
mation were examined. Equivalent increases in the
osmotic concentration of the Ringer’s solution by
adding sucrose (150 mM) did not a¡ect the level of
2,3-DHBA (data not shown). The introduction of
high KCl (70 mM) was begun. KCl signi¢cantly in-
creased cOH formation trapped as 2,3-DHBA at 15^
30 min after the beginning of KCl application (n = 6,
P6 0.05). However, no increase in 2,3-DHBA level
in the absence of KCl was observed. After removal
of KCl from the perfusate, the level of 2,3-DHBA
signi¢cantly decreased. In the presence of £uvastatin
(100 WM), when corresponding experiments were per-
formed on animals pretreated with L-NAME (5 mg/
kg i.v.), KCl (70 mM) failed to increase the level of
2,3-DHBA at 180 min application of £uvastatin (Fig.
1). However, in the absence of £uvastatin, L-NAME
inhibited [K]o-induced 2,3-DHBA formation and
the results are summarized in Fig. 3A.
The introduction of tyramine (1 mM) signi¢cantly
increased the level of 2,3-DHBA at 15^30 min after
the beginning of tyramine application (n = 6,
P6 0.05) (Fig. 2). After removal of tyramine from
the perfusate, the level of 2,3-DHBA signi¢cantly
decreased. In the presence of £uvastatin (100 WM),
when corresponding experiments were performed on
animals pretreated with L-NAME (5 mg/kg i.v.), the
same results were obtained. However, tyramine (1
mM) failed to increase the level of 2,3-DHBA for-
mation at 180 min after application of £uvastatin
and the results are summarized in Fig. 3B.
Fig. 2. E¡ect of £uvastatin on tyramine-induced cOH formation
after treatment with L-NAME. Animals treated with tyramine
(hatched bar; 1 mM) after the application of L-NAME (50
mg/kg i.v.) plus £uvastatin (solid bar; 100 WM) (closed circles)
were compared with animals treated with tyramine only (open
circles). Di¡erences between the time courses of 2,3-DHBA
were studied with the Mann-Whitney U-test. Values are means
þ S.E.M. for six animals; *P6 0.05 versus pre-tyramine value.
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3.2. E¡ect of £uvastatin on cOH formation in
ischemia/reperfusion
The presence of cOH was con¢rmed in ischemia/
reperfused rat heart. The heart was subjected to re-
gional ischemia for 15 min (210 min after probe im-
plantation) by LAD occlusion followed by reperfu-
sion for 60 min. Sodium salicylate (0.5 nmol/Wl/min)
was infused for 90 min to trap cOH, which was
formed by ischemia/reperfusion of myocardium.
After the dialysate probe was implanted in the left
ventricular myocardium, the level of 2,3-DHBA re-
mained unchanged until reperfusion. When the heart
was reperfused, a marked elevation of the level of
2,3-DHBA was observed in the heart dialysate.
This elevation was not observed outside the ischemic
area. However, in the presence of £uvastatin
(100 WM), no elevation of 2,3-DHBA in ischemia/
reperfusion was observed at 180 min after applica-
tion of £uvastatin (Fig. 4). When corresponding ex-
periments were performed with rats orally treated
with £uvastatin (at a dose of 3 mg/kg/day for
4 weeks), the same results were obtained (data not
shown). To con¢rm myocardial ischemia and reper-
Fig. 4. E¡ect of £uvastatin in ischemia/reperfused rat heart on
the formation of cOH products of salicylate. The time course of
in vivo trapping of highly reactive cOH (2,3-DHBA) in extracel-
lular £uid of myocardium is described in the text. The £uvasta-
tin (closed circles ; 100 WM)-treated group of perfusion-ischemia
(solid bar)-reperfusion was compared with the control group
(open circles). Values are means þ S.E.M. for six animals. Dif-
ferences between the time courses of the levels of 2,3-DHBA
were studied by means of the Mann-Whitney U-test. *P6 0.05
versus the level of 2,3-DHBA before ischemia.
Fig. 3. E¡ect of L-NAME and £uvastatin on KCl- or tyramine-induced cOH formation. High KCl (70 mM; A) or tyramine (1 mM;
B) was added to animals pretreated with L-NAME (5 mg/kg i.v.) or tyramine (1 mM). The levels of 2,3-DHBA are given as a percent-
age of the value measured just before the application of KCl or tyramine. Each column and vertical bar indicates the mean þ S.E.M.
for six animals; *P6 0.05 versus the level of 2,3-DHBA of the control (ANOVA and Fisher’s test). ns, not signi¢cant.
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fusion damage, the changes in serum CPK after re-
perfusion were examined. Oral £uvastatin blunted
the rise in CPK (228 þ 32 versus 142 þ 19 U/ml,
n = 5, P6 0.05).
4. Discussion
The present study indicated that £uvastatin, a
HMG-CoA reductase inhibitor, is associated with
the cardioprotective e¡ect by suppressing noradrena-
line-induced cOH generation in the heart, with the
use of a £exibly mounted microdialysis technique
[19]. With this technique it is feasible to make stable
and long-term measurements of cOH. The control of
2,3-DHBA formation in the heart dialysate was
about 10% higher than in the in vitro perfusion re-
agent background (data not shown). The drugs were
administered through the microdialysis probe. Ac-
cordingly, the concentration pro¢le of the adminis-
tered compounds in the surrounding interstitial space
is unknown; in general, the extracellular concentra-
tion of a compound given through the probe would
never reach the concentration present in the dialysis
probe [22]. This is an unavoidable limitation of the
microdialysis technique that should be kept in mind
when interpreting the experimental data.
Although the bene¢cial e¡ect of £uvastatin was
antioxidative properties [11,12], the exact mechanism
is not clearly demonstrated until now. In the present
study, to test a possible link between LDL oxidation
and cOH production, an HMG-CoA inhibitor (£u-
vastatin) was used. Antioxidant substances have been
shown to attenuate myocardial dysfunction [23^25].
Oxidative modi¢cation of LDL is thought to contrib-
ute to the production of oxygen-derived free radicals
[26]. It is known that reactive oxygen species such as
cOH may be related to the oxidation of LDL [27].
Therefore, we examined whether inhibition of LDL
oxidation can reduce cOH generation. High [K]o
(70 mM) signi¢cantly increased the level of 2,3-
DHBA (Fig. 1). To determine whether L-NAME
has a radical scavenging or antioxidant e¡ect, we
examined the e¡ect of L-NAME on K depolariza-
tion-induced cOH generation. The application of
L-NAME (5 mg/kg i.v.) signi¢cantly decreased the
level of 2,3-DHBA by the action of high [K]o.
Therefore, it is possible that [K]o-induced depolari-
zation evokes cOH generation via NOS activation.
However, when corresponding experiments were per-
formed on animals pretreated with £uvastatin
(100 WM), the same results were obtained (Figs. 1
and 3A). Moreover, we con¢rmed that £uvastatin
reduced cOH formation by the action of K depola-
rization (data not shown). These results indicate that
LDL oxidation may not be mediated with NOS ac-
tivation. Although L-NAME did not a¡ect the tyr-
amine-induced cOH formation, the e¡ect of L-NAME
on [K]o-induced cOH formation was abolished (Fig.
3A,B). The precise mechanism of depolarization-in-
duced cOH generation is obscure. It is known that
NOS inhibition may inhibit depolarization-induced
NOS activation by reducing Ca2 in£ux through
the blockade of Na and Ca2 channels [28]. The
reactive oxygen species causes excessive Na entry
through the fast Na channel, leading to intracellular
Ca2 overload through the Na-Ca2 exchange sys-
tem [29]. Intracellular Ca2 overload is then consid-
ered to lead to cell death under physiological condi-
tions such as ischemia/reperfusion injury [30,31]. It is
known that O32 and NO rapidly react to form the
stable peroxinitrite (ONOO3) and then its decompo-
sition generates cOH [17,32]. However, this idea is
under discussion [33].
The interaction between depolarization and oxy-
gen free radicals in myocardium is not clear. How-
ever, the release of noradrenaline was induced by
nerve depolarization [34]. Noradrenaline may also
have a deleterious e¡ect on the myocardium by serv-
ing as a source of free radicals [35]. It is known that
noradrenaline is released from cardiac sympathetic
nerve terminals [36,37]. Therefore, when tyramine
(1 mM), a catecholamine releaser [38], was infused
through a microdialysis probe, a marked elevation in
the level of 2,3-DHBA was observed. When tyramine
was administered to animals pretreated with
L-NAME (5 mg/kg i.v.), L-NAME did not a¡ect
the tyramine-induced cOH formation (Fig. 3B). How-
ever, in the presence of £uvastatin (100 M), tyramine
failed to increase 2,3-DHBA formation. These results
indicated that LDL oxidation may be related to nor-
adrenaline-induced cOH generation, but LDL oxida-
tion may be unrelated to cOH generation via NOS
activation.
The therapeutic e¡ect of £uvastatin is controver-
sial, mainly due to a potent inhibitor of LDL oxida-
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tion with which to test this hypothesis experimen-
tally. Several experimental studies have shown that
oxygen radicals contribute to myocardial damage in-
duced by ischemia/reperfusion [39,40]. It is well
known that ischemia induces depolarization [41,42].
Therefore, we con¢rmed the e¡ect of £uvastatin on
ischemia/reperfused rat heart. Fluvastatin (100 WM)
attenuated cOH generation induced by ischemia/re-
perfusion (Fig. 4). When rats were orally treated
with £uvastatin (at a dose of 3 mg/kg/day for
4 weeks), the same results were obtained (data not
shown). Based on the present studies, it is possible
that LDL oxidation mediates ischemia/reperfusion-
induced cOH generation via depolarization in ven-
tricular muscle. According to the reaction pathway
in Fig. 5, cOH may be formed in vivo during enzyme
oxidation. The enzyme xanthine oxidase (XO) cata-
lyzes the conversion of hypoxanthine to xanthine and
simultaneously generates O32 [43]. XO resulting from
xanthine dehydrogenase during ischemia [8] is
thought to be a potential source of O32 in rat myo-
cardium. It has an extremely short half-life [20] and
rapidly undergoes dismutation yielding H2O2. Fur-
thermore, it undergoes a Fenton-type reaction in
the presence of iron and yields highly cytotoxic
cOH [44,45]. Radicals can cause tissue injury. Myo-
cardial rat heart [46,47] injury was determined by
measuring the level of CPK from the ventricular, a
technique reported previously to be correlated with
histologic determination of infarct size rat hearts.
The protective e¡ect of £uvastatin on myocardial
ischemia and reperfusion damage was examined in
rat hearts. In the group pretreated with £uvastatin
(orally at a dose of 3 mg/kg/day for 4 weeks), serum
CPK was signi¢cantly lower than that in the control
group (n = 5, P6 0.05). It is possible that inhibition
of LDL oxidation may reduce cOH generation and
hence ameliorate myocardial injury. The ECG man-
ifestations of ischemia after ligation in £uvastatin
appeared to improve. The abnormal Q waves of
the £uvastatin-pretreated group were signi¢cantly
less than in the control group (P6 0.05, n = 5)
(data not shown). Although the precise mechanism
of cOH generation in the ischemic heart is obscure,
we previously found a concomitant increase of nor-
adrenaline and cOH generation on myocardial injury
[19]. Further investigation is necessary to con¢rm the
relationship between free radical generation and
LDL oxidation. This ¢nding shows that LDL oxida-
tion may be relevant to ischemia/reperfusion-induced
cOH generation. These results suggest that inhibition
of LDL oxidation is associated with a cardioprotec-
tive e¡ect due to the suppression of noradrenaline-
induced cOH generation.
The results of the present study may be useful in
elucidating the actual mechanism of free radical for-
mation in heart disorders. These experiments in car-
diac microdialysis have versatile applications and of-
Fig. 5. The reaction pathway in rat heart illustrates the formation of hydroxyl radicals by depolarization-induced NO. NO, nitric ox-
ide; NOS, nitric oxide synthase; L-NAME, NG-nitro-L-arginine methyl ester; XO, xanthine oxidase; O32 , superoxide anion;
cOH, hy-
droxyl radical; MAO, monoamine oxidase; DOPGAL, 3,4-dihydroxyphenylglycolaldehyde.
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fer new possibilities for the in vivo study of cardiac
physiology. In the future, cardiac microdialysis heart
perfusion experiments using the hydroxylation of sa-
licylate to detect cOH generation may be useful in
answering some of the fundamental questions con-
cerning the relevance of oxidant damage in the
pathogenesis of heart disorders, such as infarction.
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